Oxford Biomedica

Oxford BioMedica (OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. We have built a sector-leading lentiviral vector delivery platform, called LentiVector®, which we use to develop in vivo and ex vivo products both in-house and with partners. We have created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. We also have a number of partnerships, including with Novartis, Sanofi, GSK and Orchard Therapeutics, where we have long-term economic interests in other potential gene and cell therapy products. OXB is based across four locations in Oxfordshire, UK.